Active lupus in Argentina: Results of a multicenter and national registry

LupusPublished 8 Nov 2023Cross-sectional study

Cite

Authors' conclusion

Active disease was associated with shorter time to diagnosis, worse outcomes (SDI and hospitalizations) and renal, neurological and serosal disease.

Study context

Methodological detailsmulticentre, national registry

As reported in the abstract

Remission off-treatment1.6%

LDA-TC0.8%

mLLDAS12.1%

Active disease85.4%

Odds ratio (95% CI)P value

Pleuritisassociation with active disease, multivariable

2.1(1.2–3.9)

P = 0.007

Persistent proteinuriaassociation with active disease, multivariable

2.5(1.2–5.5)

P ≤ 0.011

Nephritisassociation with active disease, multivariable

2.5(1.2–5.6)

P = 0.018

Hospitalizationsassociation with active disease, multivariable

8.9(5.3–16.0)

P ≤ 0.001

Age at registry entrynegatively associated with active disease, multivariable

0.9(0.9–1.0)

P = 0.029

Observational data: associations, not effects.

Outcome	P value
Univariate: active disease vs mLLDASActive disease vs mLLDAS	P ≤ 0.001
Univariate: active disease vs mLLDASActive disease vs mLLDAS	P ≤ 0.001
Univariate: active disease vs mLLDASActive disease vs mLLDAS	P ≤ 0.001
Univariate: active disease vs mLLDASActive disease vs mLLDAS	P = 0.022
Univariate: active disease vs mLLDASActive disease vs mLLDAS	P ≤ 0.001
Univariate: active disease vs mLLDASActive disease vs mLLDAS	P ≤ 0.001
Univariate: active disease vs mLLDASActive disease vs mLLDAS	P ≤ 0.001

Univariate: active disease vs mLLDAS

Greater use of immunosuppressive therapies and higher doses of prednisone in active disease vs mLLDAS

Authors: Quintana RM, García M, Garcia L, Gobbi C, Alba P, Bellomio V, et al.
All 28 authors
Quintana RM, García M, Garcia L, Gobbi C, Alba P, Bellomio V, Roverano S, Alvarez AP, Graf CE, Pisoni C, Spindler A, Gomez C, Figueredo HM, Papasidero S, Paniego R, de la Vega MC, Civit E, Gonzalez Lucero L, Martire MV, Aguila Maldonado R, Gordon S, Micelli M, Nieto R, Rausch G, Alarcón GS, Pons-Estel B, Pons-Estel G, SLE Study Group from the RELESSAR Registry
Journal: Lupus
Published: 8 Nov 2023
DOI: 10.1177/09612033231209601
PubMed: 37936393

Remission off-treatment: SLEDAI = 0, without prednisone and immunosuppressive drugs
Low disease activity Toronto Cohort (LDA-TC): SLEDAI ≤2, without prednisone or immunosuppressive drugs
mLLDAS: SLEDAI ≤4, no activity in major organ systems and no new features, prednisone ≤10 mg/day and/or immunosuppressive drugs (maintenance dose)
Active disease: SLEDAI >4 and prednisone >10 mg/day and immunosuppressive drugs

Active lupus in Argentina: Results of a multicenter and national registry. Lupus. Published 8 November 2023. doi:10.1177/09612033231209601

Composed by AI from the published abstract and checked against it. How Briefs are made →